| GTO ID | GTC3691 |
| Trial ID |
NCT06173518
|
| Disease |
B Cell Acute Lymphoblastic Leukemia
|
B Cell Non-Hodgkin's Lymphoma
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | obe-cel|Obecabtagene autoleucel|AUTO1 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Single-Arm, Open-Label, Multi-Centre, Phase Ib Study Evaluating the Safety and Preliminary Efficacy of AUTO1 in Pediatric Patients With CD19-Positive Relapsed/ Refractory (r/r) B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B Cell Non-Hodgkin Lymphoma (B NHL) |
| Year | 2023 |
| Country | United Kingdom|United States |
| Company sponsor | Autolus Limited |
| Other ID(s) | AUTO1-PY1|2023-506307-26-00 |